ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Immunosuppression"

  • 2019 American Transplant Congress

    Oral Preconditioning of Donors after Brain Death with Calcineurin Inhibitors vs. Inhibitors of Mammalian Target for Rapamycin in Pig Kidney Transplantation

    S. Abbasi Dezfouli1, M. Golriz1, O. Ghamarnejad1, E. Khajeh1, S. Mohammadi1, M. Nikdad1, A. Majlesara1, M. Sabagh1, P. Fathi1, S. Shafiei1, M. Kentar2, A. Younsi2, C. Eckert3, T. Poth3, A. Mehrabi1, A. Nickkholgh1

    1Department of General, Visceral, and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany, 2Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany, 3Department of Pathology, University of Heidelberg, Heidelberg, Germany

    *Purpose: The systemic inflammatory cascade triggered in donors after brain death (DBD) enhances the ischemia-reperfusion injury (IRI) after organ transplantation. Data regarding donor preconditioning with…
  • 2019 American Transplant Congress

    Evaluation of Envarsus XR in African American Kidney Transplant Recipients

    L. R. Lineberger1, E. Hollinger2, N. Kenyon1, M. Brokohf1, N. Alvey1

    1Pharmacy, Rush University Medical Center, Chicago, IL, 2Rush University Medical Center, Chicago, IL

    *Purpose: This study is being conducted to evaluate the clinical impact of the utilization of tacrolimus LCP (TAC-LCP) compared to tacrolimus immediate release (TAC-IR) in…
  • 2019 American Transplant Congress

    Long-Term Outcomes of Early Conversion to Sirolimus-Based Immunosuppression in Children with Living Donor Kidney Transplants

    B. Stotter1, S. Lui1, E. Weller2, L. Ganapathi1, M. Ferguson1, A. Traum1, M. Somers1, N. Rodig1

    1Pediatrics, Boston Children's Hospital, Boston, MA, 2Biostatistics and Research Design Center, Boston Children's Hospital, Boston, MA

    *Purpose: Following kidney transplantation (KTx), calcineurin inhibitor (CNI)-based maintenance immunosuppression (IS) can be associated with nephrotoxicity and other complications including viral infections and malignancy. Mammalian…
  • 2019 American Transplant Congress

    Impact of Protease Inhibitor-Based Anti-Retroviral Therapy on Tacrolimus Intrapatient Variability in HIV+ Kidney Transplant Recipients

    M. H. Cooper, I. E. Dunne, S. A. Kuten, A. E. Cantwell, E. A. Graviss, D. T. Nguyen, M. J. Hobeika, A. O. Gaber

    Houston Methodist Hospital, Houston, TX

    *Purpose: High tacrolimus (FK) intra-patient variability (IPV) has been associated with inferior outcomes in solid organ transplantation. HIV+ transplant recipients have been shown to experience…
  • 2019 American Transplant Congress

    Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.

    J. Arreola Guerra1, R. Reyes Acevedo2, A. Chew Wong1, F. Haro Alcalde1, L. Zuñiga Macias1, R. Delgadillo Castañeda2, R. Villafan3

    1Internal Medicine and Nephrology, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, 2Transplantation, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico, 3Universidad Autonoma de Aguascalientes, Aguascalientes, Mexico

    *Purpose: Tacrolimus (TAC) is part of the immunosuppression scheme of more than 95% of patients after kidney transplantation in Mexico. Low TAC tacrolimus trough levels…
  • 2019 American Transplant Congress

    Donor Derived Neoplasia: Will It Be a Risk after Clinical Pig Organ Xenotransplantation?

    A. Jagdale1, H. Iwase1, E. Klein2, D. Cooper1

    1Surgery, University of Alabama at Birmingham, Birmingham, AL, 2Surgery, University of Pittsburgh, Pittsburgh, PA

    *Purpose: The survival of the nonhuman primates with life-supporting pig kidney grafts has increased substantially (to >1 year). As clinical pig organ xenotransplantation draws closer,…
  • 2019 American Transplant Congress

    Utilization of LCP-Tacrolimus (ENVARSUS XR) in Simultaneous Pancreas and Kidney (SPK) Transplant Recipients

    J. Torabi, A. Campbell, E. Akalin, M. Ajaimy, Y. Azzi, C. Pynadath, L. Liriano-Ward, J. P. Rocca, J. A. Graham

    Montefiore Medical Center, Bronx, NY

    *Purpose: The use of extended release tacrolimus (LCPT) allows for slow release of drug and once-daily dosing in transplant recipients. The improved bioavailability and decreased…
  • 2019 American Transplant Congress

    Breaking Concepts: 10-year Follow-Up of the Everolimus versus Azathioprine Heart Transplant Multi-National Study

    J. A. Kobashigawa1, R. Starling2, E. Passano1, P. Bernhardt3, B. Azarbal1, R. Cheng1, F. Esmailian1, K. Khush4, D. Mancini5, J. Patel1, T. Sato1, S. Varnous6

    1Smidt Heart Institute at Cedars-Sinai, Los Angeles, CA, 2Cleveland Clinic, Cleveland, OH, 3Novartis Pharmaceuticals, Basel, Switzerland, 4Stanford University, Palo Alto, CA, 5Mount Sinai, New York, NY, 6APHP, Pitié‐Salpétrière, Sorbonne University, Paris, France

    *Purpose: This study is the 10-year follow-up of a randomized double-blind prospective trial that compared everolimus (1.5 mg or 3 mg) to azathioprine. In this…
  • 2019 American Transplant Congress

    Belatacept Treated Patients Experience Improved Health-Related Quality of Life and Lower Symptom Distress Compared to Cyclosporine Treated Patients: An Analysis of the Benefit and Benefit-EXT Cohorts

    M. J. Everly1, I. Purnajo1, J. L. Beaumont1, M. Polinsky2, E. Alemao2

    1Terasaki Research Institute, Los Angeles, CA, 2Bristol Myers Squibb, Princeton, NJ

    *Purpose: New immunosuppressive agents in transplant should not only be efficacious but also help patients feel better (i.e. lower patient reported symptoms and improve health…
  • 2019 American Transplant Congress

    Islet Xenotransplantation: A Quest for Clinically Available Immunosuppression Regimens

    Z. W. Fitch1, Q. Gao1, R. P. Davis1, M. S. Mulvihill1, M. Song1, F. Leopardi1, M. Ribeiro1, T. How1, K. Reimann2, G. R. Devi1, B. H. Collins1, A. D. Kirk1

    1Surgery, Duke University, Durham, NC, 2University of Massachusetts, Worcester, MA

    *Purpose: Porcine islet xenotransplantation has progressed significantly in non-human primate (NHP) studies. However, all successful NHP studies have relied upon immunosuppressive regimens that utilize drugs…
  • « Previous Page
  • 1
  • …
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • 138
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences